Literature DB >> 31907164

Rising to the challenge of multimorbidity.

Christopher J M Whitty1, Carrie MacEwen2, Andrew Goddard3, Derek Alderson4, Martin Marshall5, Catherine Calderwood6, Frank Atherton7, Michael McBride8, John Atherton9, Helen Stokes-Lampard5, Wendy Reid10, Stephen Powis11, Clare Marx12.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 31907164      PMCID: PMC7190283          DOI: 10.1136/bmj.l6964

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
Life expectancy has improved remarkably over the past four decades thanks to improved medical and public health practice based on advances in science. Greater specialisation in medical sciences and by the clinical teams delivering care has contributed to improved clinical outcomes, and many more people are enjoying life relatively unaffected by disease from early childhood through to beyond retirement age. The proportion of patients who have two or more medical conditions simultaneously is, however, rising steadily. This is currently termed multimorbidity, although patient groups prefer the more intuitive “multiple health conditions.”1 In high income countries, multimorbidity is mainly driven by age,2 and the proportion of the population living with two or more diseases is steadily increasing because of demographic change. This trend will continue. Multimorbidity is, however, not restricted to older citizens. Being less advantaged socioeconomically accelerates the process, so in deprived areas multimorbidity occurs earlier in life.3 Children or young adults with serious congenital or acquired impairments often have multiple physical or mental illnesses,4 and the interaction between mental and physical health makes each harder to treat.5 Certain periods of life, including pregnancy, increase the probability that multiple conditions will present simultaneously. Although this transition is happening most rapidly in industrialised countries, it is already increasing in middle income countries and will become a global problem.6 The multimorbidity trend presents challenges to the entire medical profession, from general practice and community care to acute and long term hospital settings. Greater specialisation, especially for hospital based doctors, has improved our ability to treat single diseases, but unless we react to the increase in multimorbidity it will disadvantage the increasing proportion of patients with multiple seemingly unrelated diseases. Treating each disease in a patient as if it exists in isolation will lead to less good outcomes and complicate and duplicate interactions with the healthcare system.7 Training from medical school onwards, clinical teams, and clinical guidelines, however, all tend to be organised along single disease or single organ lines. As a result, a single patient may take multiple drugs recommended by different guidelines and see several specialists treating subcomponents of their overall health problem in isolation. Medical science is also disease based. Clinical trials still often exclude people who have more than one condition. Good vertical integration exists from bench to bedside for a single condition or disease, but there is little or no horizontal integration between diseases that often coexist.8 This will require an intellectual shift and rethinking some elements of our research, training, and practice in virtually every discipline.

Cluster medicine

The shift includes moving from thinking about multimorbidity as a random assortment of individual conditions to recognising it as a series of largely predictable clusters of disease in the same person. Some of these clusters will occur by chance alone because individuals are affected by a variety of commonly occurring diseases. Many, however, will be non-random because of common genetic, behavioural, or environmental pathways to disease. Identifying these clusters is a priority and will help us to be more systematic in our approach to multimorbidity. All doctors know the clusters of disease around smoking, diabetes, HIV, or obesity. Known clusters affect multiple organs with multiple pathological processes. The cluster around diabetes is a good example, with the common serious disease affecting the heart, nervous system, skin, peripheral vasculature, and eyes. Diabetologists already provide care for the cluster of multiorgan diseases around diabetes, and some specialties, such as geriatrics or general practice, have multimorbidity at their heart. For most, however, training and service organisation are not optimised to face a multimorbidity dominated future. Bringing together the undoubted benefits of specialism with a more systematic approach to the realities of dealing with patients with multiple diseases is possible but will not happen spontaneously. It is possible and desirable to have both a specialist and a generalist skill set; a specialist without generalist skills will be ill equipped to deal with many of their patients. Osler’s aphorism, “Care more particularly for the individual patient than for the especial features of the disease,” is increasingly important. A holistic professional approach is essential. The shift back to maintaining generalism in the medical workforce, including initiatives such as Shape of Training, should accelerate and be given a greater focus in the selection, training, and reward of our future workforce. Continued increases in healthy longevity depend on this different model. Clustering of diseases, and how we might better tackle management of coexisting physical and mental health problems, should be embedded into medical training and continuous professional development, including for specialists. Medical schools, the royal colleges, guideline groups, the General Medical Council, and the governments of the UK need to work together with the whole profession to tackle this. The pattern of health and disease in our population is changing, and as a profession we must respond.
  6 in total

1.  Combined impacts of multimorbidity and mental disorders on frequent emergency department visits: a retrospective cohort study in Quebec, Canada.

Authors:  Myles Gaulin; Marc Simard; Bernard Candas; Alain Lesage; Caroline Sirois
Journal:  CMAJ       Date:  2019-07-02       Impact factor: 8.262

2.  Adapting clinical guidelines to take account of multimorbidity.

Authors:  Bruce Guthrie; Katherine Payne; Phil Alderson; Marion E T McMurdo; Stewart W Mercer
Journal:  BMJ       Date:  2012-10-04

3.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.

Authors:  Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie
Journal:  Lancet       Date:  2012-05-10       Impact factor: 79.321

4.  Social disparities in the prevalence of multimorbidity - A register-based population study.

Authors:  Michaela L Schiøtz; Anders Stockmarr; Dorte Høst; Charlotte Glümer; Anne Frølich
Journal:  BMC Public Health       Date:  2017-05-10       Impact factor: 3.295

5.  Prevalence and patterns of multimorbidity among the elderly in China: a cross-sectional study using national survey data.

Authors:  Ran Zhang; Yun Lu; Liuyan Shi; Songlin Zhang; Feng Chang
Journal:  BMJ Open       Date:  2019-08-18       Impact factor: 2.692

6.  Hospital Readmission of Adolescents and Young Adults With Complex Chronic Disease.

Authors:  Peter Dunbar; Matt Hall; James C Gay; Clarissa Hoover; Jessica L Markham; Jessica L Bettenhausen; James M Perrin; Karen A Kuhlthau; Morgan Crossman; Brigid Garrity; Jay G Berry
Journal:  JAMA Netw Open       Date:  2019-07-03
  6 in total
  47 in total

Review 1.  Beliefs about the body and pain: the critical role in musculoskeletal pain management.

Authors:  J P Caneiro; Samantha Bunzli; Peter O'Sullivan
Journal:  Braz J Phys Ther       Date:  2020-06-20       Impact factor: 3.377

2.  Emergency hospital admissions associated with non-communicable diseases 1998-2018 in England, Wales and Scotland: an ecological study.

Authors:  Alexander J Robbins; Alex J Fowler; Ryan W Haines; Rupert M Pearse; John R Prowle; Zudin Puthucheary
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

3.  Clustering of physical health multimorbidity in people with severe mental illness: An accumulated prevalence analysis of United Kingdom primary care data.

Authors:  Naomi Launders; Joseph F Hayes; Gabriele Price; David Pj Osborn
Journal:  PLoS Med       Date:  2022-04-20       Impact factor: 11.069

4.  Managing patients with comorbidities: future models of care.

Authors:  Gerry Rayman; Asangaedem Akpan; Martin Cowie; Rachael Evans; Martyn Patel; Sotiris Posporelis; Kieran Walsh
Journal:  Future Healthc J       Date:  2022-07

5.  Understanding multimorbidity trajectories in Scotland using sequence analysis.

Authors:  G Cezard; F Sullivan; K Keenan
Journal:  Sci Rep       Date:  2022-10-01       Impact factor: 4.996

6.  Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999-2018.

Authors:  Xunjie Cheng; Tianqi Ma; Feiyun Ouyang; Guogang Zhang; Yongping Bai
Journal:  Int J Environ Res Public Health       Date:  2022-04-14       Impact factor: 4.614

7.  Research policy for people with multiple long-term conditions and their carers.

Authors:  Natalie Owen; Leanne Dew; Stuart Logan; Simon Denegri; Lucy C Chappell
Journal:  J Multimorb Comorb       Date:  2022-06-14

8.  Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma.

Authors:  Nathanael R Fillmore; Clark DuMontier; Cenk Yildirim; Jennifer La; Mara M Epstein; David Cheng; Diana Cirstea; Sarvari Yellapragada; Gregory A Abel; J Michael Gaziano; Nhan Do; Mary Brophy; Dae H Kim; Nikhil C Munshi; Jane A Driver
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

9.  Plasma metabolites to profile pathways in noncommunicable disease multimorbidity.

Authors:  Maik Pietzner; Isobel D Stewart; Johannes Raffler; Kay-Tee Khaw; Gregory A Michelotti; Gabi Kastenmüller; Nicholas J Wareham; Claudia Langenberg
Journal:  Nat Med       Date:  2021-03-11       Impact factor: 53.440

Review 10.  Treatment burden and ability to work.

Authors:  Anna Trakoli
Journal:  Breathe (Sheff)       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.